Factors predicting inferior PFS were failure to achieve response according to international criteria, failure to achieve complete combined metabolic and morphologic (but not only metabolic) response (p < 0.005), higher IPI (p = 0.006), higher stage (p = 0.005), presence of either C-MYC or BCL2 gene rearrangements (p = 0.033; Fig. 2b), and expression of cyclin E in >12 % of tumor cells (p = 0.046; Fig. 2c). The gene discussed is BCL2; the disease is neoplasm.